Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Rhea-AI Summary

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will report first quarter 2024 financial results on May 14, 2024. The company is focused on developing a novel therapeutic for Alzheimer's disease. A conference call and webcast will be held to provide a business and financial update.

CHARLOTTESVILLE, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance. 

The webcast audio will be available via this link. 

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com. 

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
AcumenPR@westwicke.com 

 

FAQ

When will Acumen Pharmaceuticals report first-quarter results?

Acumen Pharmaceuticals will report first quarter 2024 financial results on May 14, 2024.

What is the focus of Acumen Pharmaceuticals?

Acumen Pharmaceuticals is developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease.

How can I participate in the live conference call?

To participate in the live conference call, please register using the provided link. After registration, you will receive dial-in numbers, including a PIN.

Where can I find the archived version of the webcast?

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.